Hamish joined SV in 2008 as a Venture Partner and became an Operating Partner in 2014.
He has been Interim CEO at X2-Pharma, Delenex Therapeutics and TopiVert Pharma and Chief Commercial Officer at ESBATech. He is currently a Director at Artios, TopiVert and VHSquared.
Before joining SVLS, Hamish was CEO of Cambridge Antibody Technology (“CAT”). Prior to that, he held a series of senior R&D positions at AstraZeneca/Zeneca, including Head of the Cardiovascular Therapy Area and Senior Vice-President Medical Research; he was a member of the R&D Leadership Team. Hamish started his industry career with Janssen, after working in clinical practice and cardiovascular research in the UK. He was trained as a physician.
BSc (Hons), MBBS, Pharmacology, University of London.
Outside of SV
He is a member of the UK Royal College of Physicians, and a Fellow and past Board member of the Faculty of Pharmaceutical Medicine.